Esperion Therapeutics (ESPR) Invested Capital (2018 - 2025)
Esperion Therapeutics (ESPR) has disclosed Invested Capital for 8 consecutive years, with -$42.9 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Invested Capital rose 85.32% year-over-year to -$42.9 million, compared with a TTM value of -$42.9 million through Dec 2025, up 85.32%, and an annual FY2025 reading of -$42.9 million, up 85.32% over the prior year.
- Invested Capital was -$42.9 million for Q4 2025 at Esperion Therapeutics, up from -$354.3 million in the prior quarter.
- Across five years, Invested Capital topped out at -$42.9 million in Q4 2025 and bottomed at -$410.0 million in Q3 2023.
- Average Invested Capital over 5 years is -$302.3 million, with a median of -$314.0 million recorded in 2021.
- The sharpest move saw Invested Capital crashed 4148.05% in 2021, then skyrocketed 85.32% in 2025.
- Year by year, Invested Capital stood at -$196.9 million in 2021, then crashed by 64.4% to -$323.8 million in 2022, then surged by 40.27% to -$193.4 million in 2023, then crashed by 51.0% to -$292.0 million in 2024, then surged by 85.32% to -$42.9 million in 2025.
- Business Quant data shows Invested Capital for ESPR at -$42.9 million in Q4 2025, -$354.3 million in Q3 2025, and -$378.7 million in Q2 2025.